Abstract:Many neurodegenerative diseases are characterized by accumulation of toxic protein aggregates in specific subcellular locations. Using mouse models, Peng et al. show that inhibition of the endoplasmic reticulum acetylation machinery enhances autophagy-mediated disposal of aggregates that form within the secretory pathway and rescues Alzheimer's disease.See Duran-Aniotz et al. (doi 10.1093/brain/awv401) for a scientific commentary on this article.Many neurodegenerative diseases are characterized by accumulation of toxic protein aggregates in specific subcellular locations. Using mouse models, Peng et al. show that inhibition of the endoplasmic reticulum acetylation machinery enhances autophagy-mediated disposal of aggregates that form within the secretory pathway and rescues Alzheimer's disease.The aberrant accumulation of toxic protein aggregates is a key feature of many neurodegenerative diseases, including Huntington's disease, amyotrophic lateral sclerosis and Alzheimer's disease. As such, improving normal proteostatic mechanisms is an active target for biomedical research. Although they share common pathological features, protein aggregates form in different subcellular locations. N epsilon-lysine acetylation in the lumen of the endoplasmic reticulum has recently emerged as a new mechanism to regulate the induction of autophagy. The endoplasmic reticulum acetylation machinery includes AT-1/SLC33A1, a membrane transporter that translocates acetyl-CoA from the cytosol into the endoplasmic reticulum lumen, and ATase1 and ATase2, two acetyltransferases that acetylate endoplasmic reticulum cargo proteins. Here, we used a mutant form of alpha-synuclein to show that inhibition of the endoplasmic reticulum acetylation machinery specifically improves autophagy-mediated disposal of toxic protein aggregates that form within the secretory pathway, but not those that form in the cytosol. Consequently, haploinsufficiency of AT-1/SLC33A1 in the mouse rescued Alzheimer's disease, but not Huntington's disease or amyotrophic lateral sclerosis. In fact, intracellular toxic protein aggregates in Alzheimer's disease form within the secretory pathway while in Huntington's disease and amyotrophic lateral sclerosis they form in different cellular compartments. Furthermore, biochemical inhibition of ATase1 and ATase2 was also able to rescue the Alzheimer's disease phenotype in a mouse model of the disease. Specifically, we observed reduced levels of soluble amyloid-beta aggregates, reduced amyloid-beta pathology, reduced phosphorylation of tau, improved synaptic plasticity, and increased lifespan of the animals. In conclusion, our results indicate that N epsilon-lysine acetylation in the endoplasmic reticulum lumen regulates normal proteostasis of the secretory pathway; they also support therapies targeting endoplasmic reticulum acetyltransferases, ATase1 and ATase2, for a subset of chronic degenerative diseases.

Enhancing Retromer Complex Stability Ameliorates Synaptic Dysfunction in a Mouse Model of Alzheimer's Disease

Stabilizing the Retromer Complex in a Human Stem Cell Model of Alzheimer’s Disease Reduces TAU Phosphorylation Independently of Amyloid Precursor Protein

Retromer dysfunction in amyotrophic lateral sclerosis

Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Aβ accumulation

Retromer pathways can regulate AD‐associated neuronal and microglial phenotypes

Improved Proteostasis in the Secretory Pathway Rescues Alzheimer’s Disease in the Mouse

Mitigation of synaptic and memory impairments via F-actin stabilization in Alzheimer's disease

Aging-dependent loss of functional connectivity in a mouse model of Alzheimer's disease and reversal by mGluR5 modulator

Aging-Dependent Loss of Connectivity in Alzheimer’s Model Mice with Rescue by mGluR5 Modulator

Repetitive Transcranial Magnetic Stimulation-Mediated Neuroprotection in the 5xFAD Mouse Model of Alzheimer's Disease Through GABRG2 and SNAP25 Modulation

VPS35 or retromer as a potential target for neurodegenerative disorders: barriers to progress

Enhancing Mitochondrial Proteostasis Reduces Amyloid-Β Proteotoxicity.

The Role of Retromer in Alzheimer’s Disease

Increasing the Survival of a Neuronal Model of Alzheimer's Disease Using Docosahexaenoic Acid, Restoring Endolysosomal Functioning by Modifying the Interactions between the Membrane Proteins C99 and Rab5

Retromer Dysfunction and Neurodegenerative Disease

Enhancing myelin renewal reverses cognitive dysfunction in a murine model of Alzheimer’s disease

P2‐157: BRAIN‐SPECIFIC REPRESSION OF AMPKα1 ALLEVIATES MEMORY DEFICITS AND SYNAPTIC FAILURE IN A MOUSE MODEL OF ALZHEIMER'S DISEASE

Impaired parvalbumin interneurons in the retrosplenial cortex as the cause of sex-dependent vulnerability in Alzheimer's disease

Microglial VPS35 Deficiency Impairs Aβ Phagocytosis and Aβ-induced Disease-Associated Microglia, and Enhances Aβ Associated Pathology.

VPS35-deficiency Results in an Impaired AMPA Receptor Trafficking and Decreased Dendritic Spine Maturation

Inhibition of EHMT1/2 rescues synaptic and cognitive functions for Alzheimer’s disease